A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.
The value of an inflammation-based prognostic score (Glasgow Prognostic score, GPS) was compared with performance status (ECOG-ps) in a longitudinal study of patients (n=101) with inoperable non-small-cell lung cancer (NSCLC). At diagnosis, stratified for treatment, only the GPS (HR 2.32, 95% CI 1.52-3.54, P<0.001) was a significant predictor of survival. In contrast, neither the GPS nor ECOG-ps measured at 3-6 months follow-up were significant predictors of residual survival. This study confirms the prognostic value of the GPS, at diagnosis, in patients with inoperable NSCLC. However, the role of the GPS and ECOG-ps during follow-up has not been established.
Forrest
L M
LM
University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, UK.
McMillan
D C
DC
McArdle
C S
CS
Angerson
W J
WJ
Dagg
K
K
Scott
H R
HR
D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D005260:Female; D006304:Health Status; D006801:Humans; D007249:Inflammation / Q000145:classification*; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods*; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis